CD70 and neoplasm: These combination strategies, involving CD70‐targeted therapies with chemotherapy, targeted agents, ICIs and other adjunctive approaches, have shown promise in remodelling the immunosuppressive tumour microenvironment and enhancing tumour‐specific immune responses.